Fig. 2
A2AR antagonist KW6002 attenuated EAE pathology in mice. A Full-phase injection (i.p.) of KW6002 decreased the clinical scores of EAE (n = 7/group). Two-way RM (repeated measures) ANOVA, Sidak’s multiple comparisons test. B Full-phase injection (i.p.) of KW6002 reduced the recruitment of CD3+ T cells on the CP (n = 5/group) at day 12 post-immunization. C Quantitative analysis of leukocytes CD3+ T cells on the CP in B (n = 5/group). Unpaired t test. D–G Full-phase injection (i.p.) of KW6002 downregulated the mRNA levels of ccl2, ccl5 and cxcl10 (n = 5/group). Unpaired t test. H Injection (i.p.) of KW6002 (day post-immunization (dpi) 8–14) reduced the clinical scores of EAE (n = 9/group). Two-way RM ANOVA, Sidak’s multiple comparisons test. I Injection (i.p.) of KW6002 (dpi 8–12) reduced the clinical scores of EAE (n = 7/group). Two-way RM ANOVA, Sidak’s multiple comparisons test. J Injection (i.p.) of KW6002 (dpi 8–14) reduced the recruitment of CD3+ T cells to the CP (n = 5/group) at day 12 after immunization. K Quantitative analysis of leukocytes CD3+ T cells on the CP in J (n = 5/group). Unpaired t test. L–O Injection (i.p.) of KW6002 (dpi 8–14) downregulated the mRNA levels of ccl2, ccl5 and cxcl10 (n = 5/group). Unpaired t test. P At dpi 14, the H&E staining of spinal cords from EAE mice injected (i.p.) with KW6002 or vehicle (dpi 8–14) (n = 5/group). #p < 0.05, ##p < 0.01, ###p < 0.001, *p < 0.05, **p < 0.01 and ***p < 0.001